Imbed Biosciences Receives FDA 510(k) Clearance
Imbed Biosciences recently announced significant progress in wound care by securing FDA 510(k) clearance for its new product, Microlyte® Ag/Lidocaine. This groundbreaking wound dressing is the first of its kind to integrate lidocaine specifically for managing painful skin wounds.
Understanding Microlyte® Ag/Lidocaine
Microlyte® Ag/Lidocaine represents a significant innovation in the wound care industry. Utilizing Imbed’s patented synthetic matrix, this product combines ionic and metallic silver with lidocaine, which not only provides antimicrobial protection but also serves as a local anesthetic.
Composition and Benefits
The dressing effectively releases 40mg of lidocaine hydrochloride USP per 100cm² of wound surface area, corresponding to a 4% w/w gel. This sophisticated solution is designed for the treatment of various types of wounds, including venous stasis ulcers and surgical wounds, always under the guidance of healthcare professionals.
Addressing a Big Issue in Wound Care
The wound care industry is valued at about $22 billion, with chronic wounds affecting over 8 million individuals in the U.S. Alarmingly, approximately 60% of these wounds fail to heal properly. The presence of microbial biofilms often complicates healing, contributing to excessive healthcare costs that surpass $148 billion annually.
How Microlyte® Ag/Lidocaine Facilitates Healing
This innovative dressing is specifically engineered to promote healing in challenging wounds. It plays a pivotal role in suppressing microbial growth at the wound site, maintaining a moist environment necessary for cellular regeneration, and offering lidocaine's anesthetic effects to mitigate pain.
Expert Insights on the Product
Dr. Ankit Agarwal, PhD, co-founder and Chief Scientific Officer of Imbed, expressed pride in the creation of this revolutionary dressing. “This formulation allows us to demonstrate the effective integration of silver and lidocaine in a single product, paving the way for enhanced wound care solutions,” he remarked.
Major Breakthrough in Wound Management
Michael Schurr, MD, Chair of General Surgery at Mission Hospitals, emphasized the game-changing nature of this dressing. He noted how it could significantly lower infection rates and alleviate pain, thus possibly reducing the reliance on systemic antibiotics and opioids for patients suffering from severe wounds.
Commitment to Advancing Wound Care Standards
Last year, over 100,000 units of the Microlyte® Matrix were utilized in various wound care applications. Dr. Agarwal assured that the new combination of silver and lidocaine in the Microlyte® Ag/Lidocaine reinforces their ongoing commitment to advancing wound treatment protocols.
Future Outlook for Microlyte® Ag/Lidocaine
The enhanced dressing is expected to officially launch at a significant industry event in May 2025, inviting healthcare professionals to explore its capabilities and integrate it into their treatment regimens.
About Imbed Biosciences
Imbed Biosciences is a dedicated medical device company focused on developing innovative solutions that enhance wound care. With a portfolio comprising both market-ready products and those in development, the company aims to alleviate local pain and tackle infections in complex wounds using its proprietary Microlyte® Matrix technology. Engaging with their community and healthcare professionals is vital; for more information, visit ImbedBio.com and follow them on their social platforms.
Frequently Asked Questions
What is Microlyte® Ag/Lidocaine?
Microlyte® Ag/Lidocaine is an innovative wound dressing that integrates lidocaine and silver, providing antimicrobial benefits as well as local pain relief.
Who developed Microlyte® Ag/Lidocaine?
The product was developed by Imbed Biosciences, a company dedicated to improving wound care solutions.
What types of wounds can it treat?
It is designed for partial and full-thickness wounds, including venous ulcers and surgical sites.
How does it promote healing?
The dressing maintains a moist environment for cellular growth and suppresses microbial activity, which aids in the healing process.
When will it be available?
The Microlyte® Ag/Lidocaine dressing is anticipated to launch in May 2025 during a key industry symposium.
